Molecular testing in thyroid cancer

Matthew T. Olson, Jason D. Prescott, Martha A. Zeiger

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cancer of the thyroid gland is associated with genetic aberrations including point mutations in BRAF, RET, and any of the RAS subtypes and chromosomal translocations involving known breakpoints in RET/PTC and PAX8/PPARγ. While the relationships between these molecular abnormalities and tumor carcinogenesis have been well characterized, their relationship to prognosis and usefulness in clinical care is less clear. In this chapter, we discuss the molecular aberrations, how they are detected, how they correlate with cytomorphological and histomorphological findings, and how useful the constellation of this information may be in current patient management. We also compare and contrast the currently available molecular testing strategies-the gene expression classifier and the somatic mutation panel-for stratifying risk in cytomorphologically indeterminate nodules biopsied by fine needle aspiration.

Original languageEnglish (US)
Title of host publicationMolecular Testing in Cancer
PublisherSpringer New York
Pages319-329
Number of pages11
Volume9781489980502
ISBN (Electronic)9781489980502
ISBN (Print)1489980490, 9781489980496
DOIs
StatePublished - Oct 1 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Molecular testing in thyroid cancer'. Together they form a unique fingerprint.

  • Cite this

    Olson, M. T., Prescott, J. D., & Zeiger, M. A. (2014). Molecular testing in thyroid cancer. In Molecular Testing in Cancer (Vol. 9781489980502, pp. 319-329). Springer New York. https://doi.org/10.1007/978-1-4899-8050-2_19